Highest-materiality recent filing
Vaxcyte Q2 net loss $284M; VAX-31 OPUS-1 topline data expected Q4 2026
Net loss of $284.3M in Q2 2026 vs $166.6M in Q2 2025; R&D expenses rose to $267.9M.
Vaxcyte director Heath Lukatch retires; John Markels appointed to board
Heath Lukatch retired from Vaxcyte board effective July 16, 2026; no disagreement with company.
Vaxcyte director Jacks Lee retires; Moncef Slaoui appointed to board
Jacks Lee retired from the Board effective June 17, 2026; no disagreement with the company.
Vaxcyte shareholders re-elect all three Class III directors, ratify Deloitte, approve say-on-pay
Three Class III directors re-elected: Brandicourt (116.4M for), Gilbert (114.7M for), Pickering (132.1M for); 4.4M broker non-votes.
Vaxcyte Q1 net loss $320.6M; OPUS Phase 3 enrollment completed; topline data Q4 2026
Cash $2.74B as of Mar 31, up from $2.44B Dec 31; includes $601.8M from Feb 2026 equity offering.
Vaxcyte enters $500M at-the-market equity offering; terminates prior $270.3M ATM with Jefferies
Sales agreement with Leerink Partners for up to $500M in common stock via at-the-market offerings.
Vaxcyte reports 2025 net loss of $766.6M; cash $2.44B plus $600M from Feb equity offering
Full-year 2025 net loss $766.6M vs $463.9M in 2024; R&D expenses $794.3M (up 67% YoY).
Vaxcyte raises $600.2M in public offering of 12.65M shares at $50/share
Offering of 11M shares at $50.00 public price; underwriter option for 1.65M shares exercised.
Vaxcyte boosts severance multipliers for CEO Pickering and three other execs effective Dec 31, 2025
CEO Pickering: base salary severance multiplier for Qualifying Termination increases to 1.5x (from 1.0x); CIC termination to 2.0x (from 1.5x).
Vaxcyte Q3 net loss $212.8M; cash $2.67B; VAX-31 adult pivotal study start Dec 2025
Net loss of $212.8M for Q3 2025 vs $103.1M in Q3 2024; R&D expenses $209.9M, up from $116.9M.
Vaxcyte signs 15-year manufacturing deal with Thermo Fisher's Patheon
Agreement covers formulation, fill, finish, testing at Patheon's Greenville, NC facility.
Vaxcyte Q2 net loss $166.6M, cash $2.83B; VAX-31 Phase 3 on track for Q4 start
Net loss $166.6M for Q2 2025 vs $128.7M a year ago; R&D expenses $194.2M, up from $131.5M.
Vaxcyte shareholders re-elect all three Class II directors and approve officer exculpation
John Furey reelected with 120.7M For vs 0.4M Withheld; Jacks Lee 107.3M For vs 13.8M Withheld.
Vaxcyte Q1 net loss $140.7M; VAX-24 infant data positive, VAX-31 Phase 3 set for mid-2025
Net loss $140.7M vs $95.0M YoY; cash, equivalents & investments $2.95B at March 31, 2025.
Vaxcyte appoints Dr. Olivier Brandicourt to board of directors
Appointment effective May 1, 2025 as a Class III director with term expiring at 2026 annual meeting.
Vaxcyte reports positive VAX-24 infant Phase 2 topline; selects mid dose; announces VAX-XL
VAX-24 well-tolerated; safety similar to Prevnar 20; no related serious adverse events.
Vaxcyte reports Q4 2024 net loss of $137.1M; cash $3.13B; VAX-31 Phase 3 on track for mid-2025
Net loss Q4 2024: $137.1M; full year 2024: $463.9M vs $402.3M in 2023.
Vaxcyte amends HQ lease to 258,581 RSF, subleases 16,731 SF to Iovance Biotherapeutics
Amended lease expands premises from ~113k to 258,581 RSF across floors 1-6, phased move-ins Feb 2025 through June 2026.
Vaxcyte reports Q3 net loss $103M; cash $3.27B after $1.4B follow-on
Net loss of $103.1M for Q3 2024 vs $92.7M in Q3 2023.
Vaxcyte raises $1.42B in underwritten public offering of common stock and pre-funded warrants
Sold 10,194,175 shares at $103.00/share and pre-funded warrants to purchase 2,427,184 shares at $102.999/warrant.
Vaxcyte reports positive Phase 1/2 data for VAX-31; all serotypes meet immunogenicity criteria
VAX-31 showed robust OPA responses for all 31 serotypes at all doses; safety profile similar to Prevnar20.
Vaxcyte Q2 net loss $128.7M; cash $1.85B; VAX-31 adult data due Sept 2024
Net loss $128.7M for Q2 2024 vs $68.3M in Q2 2023; R&D expenses $131.5M, up from $72.7M.
Vaxcyte appoints John P. Furey to Board of Directors, effective July 2, 2024
John P. Furey appointed as Class II director; term expires at 2025 annual meeting.
Vaxcyte shareholders re-elect Class I directors, ratify Deloitte as auditor, approve say-on-pay
Annie Drapeau re-elected with 82,886,170 votes for; Teri Loxam with 96,840,846; Carlos Paya with 96,685,408.
Vaxcyte reports Q1 net loss $95M, cash $1.9B; VAX-31/24 enrollment complete
Cash, equivalents and investments $1.9B at March 31, 2024, up from $1.24B at Dec 31, 2023, including $816.5M net from Feb offering.
Vaxcyte FY23 net loss $402M; VAX-31 adult Phase 1/2 topline data Q3 2024; cash $1.24B
Net loss of $402.3M for FY2023 (vs $223.5M in FY2022); cash, equivalents & investments $1.24B as of Dec 31, 2023.
Vaxcyte Raises $816.5 Million in Public Offering of Common Stock and Pre-Funded Warrants
Underwriting agreement with BofA, Jefferies, Leerink, Evercore for 10,937,500 shares at $64.00 per share and 781,250 pre-funded warrants at $63.999 per warrant.
Vaxcyte appoints Jacks Lee to Board of Directors, effective Nov 27, 2023
Jacks Lee appointed as Class II director, term expires at 2025 annual meeting.
Vaxcyte exercises option for manufacturing rights; pays $50M upfront
Exercised option on Nov 21, 2023; paid $50M cash; owes $25M within 6 months.
Vaxcyte Q3 net loss $92.7M; FDA clears VAX-31 IND; VAX-24 Phase 3 agreed
Net loss $92.7M vs $57.9M YoY; cash $1.43B (up from $957.9M Dec 2022).
Vaxcyte subsidiary signs commercial manufacturing deal with Lonza for pneumococcal vaccine
Lonza will build a dedicated suite in Visp, Switzerland to manufacture drug substance for Vaxcyte's pneumococcal conjugate vaccine franchise.
Vaxcyte and Sutro finalize Form Definitive Agreement; amend license terms
On Sep 28, 2023, Vaxcyte and Sutro mutually agreed on the Form Definitive Agreement to become effective if Vaxcyte exercises the option to source extract.
Vaxcyte expands HQ by assuming 36,593 sq ft lease at 825 Industrial Road, San Carlos
Assumed lease from Codexis for ~36,593 rentable sq ft at 825 Industrial Road, San Carlos.
Vaxcyte reports Q2 net loss $68.3M, cash $1.44B, VAX-24 infant Phase 2 advanced to Stage 2
Cash $1.44B as of June 30, includes $545M net from April public offering.
Vaxcyte stockholders re-elect three Class III directors, ratify Deloitte, approve say-on-pay
Class III directors Halley Gilbert, Michael Kamarck, and Grant Pickering re-elected with over 61M votes each.
Vaxcyte reports Q1 net loss $60.5M; VAX-24 Phase 2 meets endpoints in adults 65+
Net loss of $60.5M in Q1 2023 vs $39.0M in Q1 2022; R&D expenses $58.1M, up from $31.7M.
Vaxcyte raises $544.5M net via public offering of stock and pre-funded warrants
Issued 11.2M shares at $41.00 and pre-funded warrants for 1M shares at $40.999 each.
VAX-24 2.2mcg dose met OPA non-inferiority for 18 of 20 serotypes common with Prevnar 20 and superiority for all four unique serotypes.
Agreement effective March 1, 2023, for manufacturing process development and production of polysaccharide antigens, eCRM carrier, and conjugated drug substances.
Vaxcyte reports Q4 2022 net loss of $78.1M; cash $957.9M; VAX-24 infant IND cleared
Net loss of $78.1M for Q4 2022 and $223.5M for full year 2022; R&D expenses $51.6M and $169.5M respectively.
Vaxcyte increases ATM equity offering capacity from $150M to $400M
Amendment to Sales Agreement with Jefferies raises aggregate offering amount to $400M.
Vaxcyte in option deal with Sutro for cell-free extract; $22.5M upfront
Upfront consideration of $22.5M: $10M cash, $7.5M stock (due within 5-7 days), $5M after Form Definitive Agreement.
Vaxcyte appoints Elvia Cowan as principal accounting officer effective Jan 1, 2023
Elvia Cowan, 50, currently SVP Finance since July 2022, appointed principal accounting officer.
Q3 net loss $57.9M (vs $26.6M YoY); R&D $47.7M (up from $20.4M) on Phase 3/IND activities.
Vaxcyte prices $650.7M underwritten public offering of common stock and pre-funded warrants
Selling 15M shares at $32.00/share and pre-funded warrants for 3.75M shares at $31.999 each.
Vaxcyte VAX-24 Phase 1/2 meets all endpoints; 2.2mcg dose advances to Phase 3
VAX-24 safety profile similar to Prevnar 20 at all doses; no related SAEs or chronic illnesses.
Vaxcyte Q2 net loss $48.5M; VAX-24 Phase 2 fully enrolled with topline data expected Oct/Nov 2022
Cash, equivalents and investments of $361.4M at June 30, 2022 (vs. $273.1M at Dec. 31, 2021).
Vaxcyte annual meeting: directors re-elected, say-on-pay approved, auditor ratified
Peter Hirth re-elected as Class II director with 44,840,461 votes for, 2,557,604 withheld.
Vaxcyte Q1 net loss $39M, cash $352M; VAX-24 topline results due end-2022
Q1 net loss $39.0M vs $21.2M YoY; R&D $31.7M, G&A $7.5M.
Vaxcyte enters manufacturing pact with Lonza for pneumococcal vaccine
Master Services Agreement effective March 22, 2022 for clinical manufacturing of Vaxcyte's PCV.
On July 13, 2026, Heath Lukatch notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of July 16, 2026.
Concurrently, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed John Markels to the Board as a Class II director, effective as of July 16, 2026.
On June 17, 2026, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Moncef Slaoui to the Board as a Class II director, which appointment became effective immediately.
On June 17, 2026, Jacks Lee notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of June 17, 2026.
On May 1, 2025, upon recommendation of the Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed Dr. Olivier Brandicourt to the Board as a Class III director, which appointment became effective immediately.
the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed John P. Furey to the Board as a Class II director, which appointment became effective on July 2, 2024.
appointed Jacks Lee to the Board as a Class II director
On December 6, 2022, the Board of Directors of Vaxcyte, Inc. (the “Company”) appointed Elvia Cowan, its Senior Vice President, Finance, as the Company’s principal accounting officer, effective January 1, 2023.
On September 16, 2021, Patrick Heron, a director of the Vaxcyte, Inc. (the “Company”) and member of the Audit Committee, and Rob Hopfner, a director of the Company and member of the Nominating and Corporate Governance Committee (the “Nominating Committee”), both resigned as members of the Company’s Board of Directors (the “Board”), which resignations became effective on September 16, 2021.
On September 16, 2021, upon recommendation of the Nominating Committee, the Board appointed Annie Drapeau and Teri Loxam to the Board as Class I directors, which appointments became effective on September 16, 2021.
On September 16, 2021, Patrick Heron, a director of the Vaxcyte, Inc. (the “Company”) and member of the Audit Committee, and Rob Hopfner, a director of the Company and member of the Nominating and Corporate Governance Committee (the “Nominating Committee”), both resigned as members of the Company’s Board of Directors (the “Board”), which resignations became effective on September 16, 2021.
On September 16, 2021, upon recommendation of the Nominating Committee, the Board appointed Annie Drapeau and Teri Loxam to the Board as Class I directors, which appointments became effective on September 16, 2021.
Max materiality 0.90 · Median 0.70 · Most common event other_material